News 17.12.2025 Zurich, Switzerland - Topadur Pharma AG, a clinical-stage biotechnology company developing innovative therapies for vascular regeneration, today announced the appointment of PD Dr. Matthias Schäfer as Chief Executive Officer. Dr. Schäfer joined Topadur in 2024 as Chief Innovation Officer and Deputy CEO and now assumes executive leadership as the company advances...
News 15.12.2025 DINAMIQS, a Siegfried company, today announced a licensing agreement with ExcellGene to access its HEKExpress® and HEK2Express® suspension cell line technologies. These will be used in GMP manufacturing of recombinant Adeno-associated virus (rAAV) and Lentivirus (rLV) vectors for both in-vivo and ex-vivo gene therapies. Eduard Ayuso, Chief Technical Officer at DINAMIQS:...
News 15.12.2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the formation of a Scientific Advisory Board (SAB) for its radiopharmaceuticals,...
News 12.12.2025 Cologne, Germany, December 11, 2025 – DISCO Pharmaceuticals (“DISCO”) today announced the appointment of seasoned biotech leader Mark Manfredi, Ph.D., as Chief Executive Officer (CEO), as well as the final close of a €36 million seed financing round to advance the company’s pipeline of surfaceome-targeted drug candidates. The seed expansion...
News 11.12.2025 With the acquisition of GHZ Gewerbe- und Handelszentrum AG, Swiss Life Asset Managers is strengthening its position in the life science sector and further expanding its position as a leading real estate investor. The Schlieren location and all employees will be retained. Founded in 1984, Gewerbe- und Handelszentrum Schlieren (GHZ) is...